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Abstract: A porous poly(L-lactic acid)/β-tricalcium phosphate (PLLA/β-TCP) composite 
scaffold was fabricated using a novel technique comprising powder mixing, compression 
molding, low-temperature treatment, and particulate leaching without any organic solvent. The 
effect of this scaffold on osteoblast proliferation and differentiation was evaluated in vitro. The 
fabricated scaffold had a homogeneously interconnected porous structure with a porosity of 
70% and compressive strength of 1.35 MPa. The methylthiazol tetrazolium values and alkaline 
phosphatase (ALP) activity of osteoblasts seeded on the solvent-free scaffold were significant 
higher than those of the control. Using real-time PCR, gene expressions of ALP, osteocalcin, 
and type 1 collagen were shown to be upregulated. As the method does not use any organic 
solvent, it eliminates problems associated with organic solvent residue and therefore improves 
the cell compatibility. It has a promising potential for the preparation of porous scaffold for 
bone tissue engineering.
Keywords: biocompatibility, biomaterials, composites, poly(L-lactic acid), β-tricalcium 
phosphate
Introduction
The repair of bone defects is of key interest in orthopedics and in dental implant 
treatment. Although some ceramics such as hydroxyapatite and tricalcium phosphate 
(β-TCP) are currently available as bone graft substitutes, none has been demonstrated 
to be fully satisfactory.1 The brittleness of calcium phosphate ceramics confines them to 
nonload or low-load bone repairs. Poly(L-lactic acid) (PLLA) is also extensively used 
for the regeneration of bone tissue, because of its biocompatibility and biodegradation.2 
However, the acid degradation products of PLLA can result in aseptic inflammation 
of tissues, and the hydrophobicity of PLLA may significantly affect cell attachment 
ability. An approach to overcome these limitations is the use of ceramic–polymer 
composite materials.2–4
Several methods have been reported to prepare porous composite scaffolds, such 
as porogen leaching,5 thermally induced phase separation,6 and freeze-extraction and 
freeze-gelation methods.7 However, in these methods, a large number of organic sol-
vents and surfactants are used which form residues in the composite scaffolds. These 
residual organic solvents and surfactants have the potential to harm cell and tissue.8 
Furthermore, in these methods, the polymer is usually dissolved in an organic solvent 
and then the ceramic particles are added. After the solvent is volatilized, the ceramic 
particles are usually coated by polymer, which leads to the hydrophobic surface of 
the scaffold.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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To solve the problems of residual organic solvent and 
cell compatibility, we previously demonstrated a novel 
technique comprising powder mixing, compression molding, 
low-temperature treatment, and particulate leaching (PCLP) 
to prepare PLLA/β-TCP composite scaffolds without using 
any organic solvent.9 But in the previous study, the in vitro 
biological evaluation of the scaffold prepared by this novel 
method was not comprehensively investigated. Therefore, 
we further studied the effect of this composite scaffold on 
in vitro osteoblast proliferation and differentiation, compared 
with that of scaffolds made by the conventional solvent 
casting method.
Experimental
Preparation of PLLA/β-TcP scaffold
The PLLA/β-TCP scaffold was prepared by the PCLP 
method reported previously with minor modification.9 Briefly, 
PLLA and β-TCP (diameter: Dav = 1.31–2.34 µm) were 
mixed together (50:50, w/w), and further homogeneously 
mixed with sieved sodium chloride (porogen, diameter: 
200–400 µm) by magnetic force stirring for 30 minutes 
before loading into a disk mold (inner diameter: 13 mm). 
PLLA (MW: 600 kDa) was purchased from Chengdu Organic 
Chemicals Co. Ltd., Chinese Academy of Sciences. The 
weight ratio of salt particulates to compounds (PLLA and 
β-TCP) used was 2.4:1, ie, the percentage of salt in the total 
mixture weight was 70.59%. After the mixture and stainless 
steel mold were heated at 170°C for 10 minutes, and the 
mixture in mold was quickly pressed at a pressure of 10 MPa 
for 5 minutes to yield a solid disc. Next, the prepared com-
posite disc was further heated at 200°C for 30 minutes with 
conversion every 5 minutes during the heating period. The 
sodium chloride particulates were subsequently removed 
from the composites by leaching the composites in distilled 
water with shaking for 72 hours, with water changed every 
6 hours until no precipitation occurred by adding silver nitrate 
into the changed water. The composites were then dried in 
a vacuum oven for further use. For the control experiments, 
composites were fabricated by conventional solution cast-
ing/film crushing/compression molding/particulate leaching 
method from 5% w/v chloroform solution.
scaffold characterization
Scaffold porosity was measured using the Archimedes 
immersion technique as described previously.10 Scaffold pore 
diameter and morphology were observed with a scanning 
electron microscopy (SEM) (FEI Inspect F, The   Netherlands) 
after gold coating. The compressive strength of the scaf-
fold was evaluated on an AG-10TA electronic apparatus 
  (Shimadzu, Japan).
Primary culture of calvarial osteoblasts
Osteoblastic cells were enzymatically isolated from neonatal 
Sprague-Dawley rats as described preciously.11 Briefly, dis-
sected calvariae were sequentially digested for 10-minute 
intervals with 0.1% type I collagenase (Sigma-Aldrich, 
St Louis, Mo) and 0.25% trypsin (Sigma-Aldrich) at 37°C. 
Cells obtained from the second to the fourth digestions were 
incubated in DMEM (Gibco) with antibiotics and 10% fetal 
bovine serum (Gibco). At about 90% confluence, cells were 
trypsinized and subcultured. To confirm that cultures were 
osteoblast-enriched, mineralized bone nodule formation assay 
and alkaline phosphatase (ALP) staining were performed. All 
experiments were performed using the cells of third passage.
scanning electron microscopy
Cell suspension (3 × 104 cells/mL, 1 mL/well) were pipetted 
on to scaffolds in the 24-well plates and incubated at 37°C. 
After 24 hours, cell morphology was visualized using an SEM 
(FEI Inspect F, The Netherlands). Scaffolds attached with cells 
were fixed in 2.5% glutaraldehyde, dehydrated, and sputter 
coated with gold/palladium prior to SEM observation.
Table 1 Specific primers designed following the cDNA sequences of each gene in GenBank
Gene GenBank accession  
number
Primers Product size
ALP NM_013059 (+), 5′-cgTcTccATggTggATTATgcT-3′ 209 bp
(–), 5′-cccAggcAcAgTggTcAAg-3′
OcN NM_013414 (+), 5′-TAccTcAAcAATggAcTTggAgc-3′ 206 bp
(–), 5′-cTggAgAgTAgccAAAgcTgAAg-3′
cOL-1 XM_213440 (+), 5′-gcATggccAAgAAgAcATcc-3′ 239 bp
(–), 5′-cTccTATgAcTTcTgcgTcTggT-3′
β-Actin NM_031144 (+), 5′-cAcggcATTgTcAccAAcTg-3′ 167 bp
(–), 5′-TTgAAggTcTcAAAcATgATcTgg-3′International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Assessment of cell proliferation
Cell proliferation was assessed using a methylthiazol tetra-
zolium (MTT, Sigma-Aldrich) method. Briefly, 50 µL MTT 
solution (5 mg/mL) was added to each well, followed by 
incubation for 4 hours at 37°C. The medium and MTT were 
then replaced by 1 mL dimethyl sulfoxide to dissolve the 
formazan crystals. After 30 minutes, 200 µL of supernatant 
was transferred to microplate wells (Falcon), and the optical 
density was quantified at a wavelength of 492 nm (HTS 7000 
p1us, PerkinElmer, USA).
Measurement of ALP activity
ALP activity was determined in cell homogenates prepared 
by ultrasonication, with an ALP diagnostic reagent of 
  p-nitrophenyl phosphate (Merit Choice Co. Ltd. Beijing, 
China). The absorbance of p-nitrophenol formed by the 
  hydrolysis of p-nitrophenyl phosphate was measured at 405 nm 
3 times every 10 minutes. Total protein content was measured 
with the Bradford method. ALP activity was then normalized 
to its protein concentration and expressed as units/g protein.
rNA extraction and quantitative  
real-time Pcr
Total RNA was extracted from each sample by the   TRIzol 
method strictly following the manufacturer’s   protocol 
(Invitrogen, Carlsbad, CA.). The first-strand cDNA 
was   synthesized from 1 µg RNA with murine leukemia 
virus reverse transcriptase (Takara, Japan), and used for 
  quantitative real-time PCR. Expression levels of represen-
tative genes, including ALP, osteocalcin (OCN), and type 1 
collagen (COL-1), were quantified with an ABI 7300 real-
time PCR system (Applied Biosystems, Foster City, CA) 
and SYBR green PCR reaction mix (Infinigen, USA). Prim-
ers and annealing temperature for each gene are listed in 
Table 1. The program used was: 50°C for 2 minutes, 95°C for 
10 minutes, 40 cycles of 95°C for 15 seconds, and annealing 
temperature for 1 minute. Melting analysis and agarose gel 
electrophoresis were performed to confirm the specificity of 
the PCR products. The relative expression levels of genes 
were analyzed using the 2−∆∆Ct method by normalizing with 
β-actin housekeeping gene expression, and presented as fold 
increase relative to the control group.
statistical analysis
Data are shown as means ± standard deviation, and were statis-
tically compared using independent-samples t tests.   Differences 
at P , 0.05 were considered statistically significant.
A B
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Figure 1 seM images of scaffolds made by PcLP method (A, C) and by conventional 
organic solvent casting method (B, D).
Abbreviations:  PcLP,  powder  mixing,  compression  molding,  low-temperature 
treatment, and particulate leaching; seM, scanning electron microscopy.
Results and discussion
Figure 1A shows the interconnected pore structure of PCLP 
scaffold made by the organic solvent-free method. The 
Archimedes immersion technique showed the porosity of 
the PCLP scaffold to be around 70%. Scaffold porosity and 
pore size are important features for evaluating biomaterial 
properties for tissue engineering. Sufficient pore size allows 
maximum osteoconduction with sufficient nutrient transfer 
for optimal tissue growth, although there are conflicting 
reports on the pore size that favors new bone formation and 
growth12–14 The porosity and pore structure can be controlled 
by salt weight, particulate size, and polymer fraction. Our 
previous study indicated that scaffold porosity increases with 
increasing sodium chloride particulate size. However, the 
compressive strength of PLLA/β-TCP scaffold decreased 
with increasing porosity.9 Therefore, we used the sieved 
sodium chloride with a particulate size of 200–400 µm and 
weight ratio of 70.59% to prepare the composites. As shown 
in Figure 2, the compressive strength of PCLP scaffold was 
1.35 MPa, significantly higher than that of solvent-casting 
composites. This result indicates that the conditions used in 
the current study could achieve a highly porous scaffold with 
uncompromised compressive strength.
Figure 3 shows the morphological features of osteoblasts 
cultured on the scaffolds for 1 day. The osteoblasts attached 
and spread on the surface well. SEM images indicate that 
more cells were presented in the PCLP scaffolds together 
with more distinguishable and typical cell shape. Cells extend 
filopodia to the surface of PCLP scaffolds, and multiple point 
attachments were observed.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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As shown in Figure 4A, PCLP composites made by the 
organic solvent-free method demonstrated superior cell 
proliferation compared with the composites prepared by 
solvent casting. Especially in the first 7 days, cells seeded on 
the PCLP scaffold grew rapidly while those on the solvent 
casting scaffold proliferated very slowly. This result may 
be due to the cytotoxicity of the residual organic solvent. 
These organic residues in the scaffolds may be harmful to 
adherent cells, growth factors, or nearby tissues.15,16 After 
7 days of culture, cells seeded on PCLP scaffolds grew to a 
high confluence and their proliferation slowed. Meanwhile, 
the organic residues in the control group might have been 
removed after 2 changes of culture medium (the culture 
medium was changed every 3 days). Therefore, a delayed 
proliferation was observed in the control group after 7 days 
of culture.
Figure 4B shows that the presence of PCLP scaffolds did 
increase ALP activity of osteoblasts. On day 28, ALP activity 
in PCLP scaffolds reached a peak of 12.099 ± 0.882 units/g 
protein, and slightly deceased to 9.762 ± 1.275 units/g   protein 
on day 35. Using real-time quantitative PCR, we also noted 
that expression of osteogenic differentiation-associated 
genes was upregulated by PCLP scaffolds (Figure 4C, 
4D, and 4E). These results were consistent with the report 
of Kim et al.8 There may be 2 reasons for this enhanced 
biological performance: first, the solvent-free methods we 
used   during the fabricating process, and second, the refined 
surface structure of the scaffold. As shown in Figure 1C, 
β-TCP particles disperse homogenously in the PCLP scaf-
folds and become exposed directly to the cell. It has been 
proved that bioceramics enhance osteoblast differentiation 
as well as bone regeneration.17,18 In contrast, in the solvent 
casting process the mixing of ceramic with polymer solu-
tion followed by solvent evaporation resulted in coating of 
ceramic by a polymer layer (Figure 1D). This polymer layer 
may hinder the exposure of bioceramics and subsequently 
reduce the osteogenic induction of bioceramics.16
In the conventional sintering method, the solvent-free 
process can overcome the coating of ceramic by the polymer 
layer.19 Blending of polymer, ceramic, and salt followed by 
pressure with heating, a conventional heating method, can 
reduce the degree of ceramic coating compared with the 
solvent casting method.20 But coating of ceramics by polymer 
melting can still occur, because the polymer swells during 
melting in the limited space of the mold, and polymer solu-
tion flows into the spaces within ceramics under pressure. To 
reduce this negative effect, Jung et al16 introduced a method 
of separate pressing and thermal processes; however, this 
method may compromise the strength of the composite. In 
this study, we performed a number of experiments accord-
ing to the properties of PLLA to determine the appropriate 
temperature and time of heat treatment.9 Moreover, the fabri-
cating process was divided into 2 steps: heating and pressing. 
First, we chose 170°C as the preheating temperature and 
quickly pressed at a pressure of 10 MPa for 5 minutes. Then 
the mixture was sintered at 200°C and pressed again. This 
process showed limited contact between β-TCP and polymer, 
leading to a minimum polymer coating, which results in 
superior osteoconduction to the osteoblast culture.
Another important factor affecting the ability of calcium 
phosphate-based materials to promote bone generation is 
grain size. It has been widely accepted that ceramics, metals, 
polymers, and composites with nanometer grain sizes can 
stimulate osteoblast activity, leading to faster bone formation, 
compared with micron grain sizes.21–23 In this study, the diam-
eter of β-TCP particles used was around 1.31 µm to 2.34 µm. In 
future studies, using nanoparticles may further improve scaffold   
properties.
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Figure 3 seM images of osteoblasts cultured on the scaffolds for 1 day: (A) PcLP 
scaffold; (B) solvent casting scaffold.
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Conclusion
A novel PCLP method was successfully developed to prepare 
PLLA/β-TCP scaffolds without using any organic solvent. 
The resultant scaffolds had high porosity with interconnected 
porous structure and high compressive strength. In vitro tests 
showed that cell proliferation, ALP activity, and osteogenic 
genes expression were significantly better for PCLP than for 
solvent casting scaffolds. Such a superior outcomes for the 
PCLP scaffolds can be attributed to the fact that this new 
method does not use any organic solvent. Its advantage is that 
it avoids the problems associated with solvent residues. As 
β-TCP particles disperse homogeneously in PLLA continu-
ous phase matrix, the direct exposure of these particles to 
osteoblasts also stimulates cell proliferation and osteogenic 
differentiation.
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